Melbourne, Feb 20, 2026, 16:57 (AEDT) — The session’s over.

• CSL slipped on Friday, paring back gains from its brief two-day bounce.
• New filings point to consistent buybacks, plus news of a licensing agreement with Eli Lilly.
• Next up: pace of buybacks heading into Monday, plus March dividend timing in view

CSL Ltd (CSL.AX) slipped 0.6% Friday, ending the session at A$153.27. That pullback shaved off some of the gains from a two-day run-up earlier in the week. (Investing.com Australia)

That late-week drop caught notice—investors haven’t seen much in the way of confirmation that the stock has a real floor. Right now, CSL’s filings take center stage, spelling out just how much it’s buying back and…